Investors need to pay close attention to Catalent (CTLT) stock based on the movements in the options market lately.

Catalent (CTLT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Investors including Quadria Capital and Denmark-based pharmaceutical major Novo Nordisk are among those interested in a ...

Increased demand for biologics and biosimilars is driving the demand for dual chamber prefilled syringes.Rockville, MD, Sept.

Catalent (CTLT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. The contract ...

COPENHAGEN: Denmark’s economy has become intertwined with Novo Nordisk A/S, famous for its fast-selling weight-loss ...

As Eli Lilly and Novo Nordisk continue to dominate the lucrative weight-loss drug market, smaller competitors are gearing up ...

Advance Realty Investors recently celebrated the start of the municipality’s first new office development in 20 years: a ...

Eli Lilly is investing $1.8 billion across two manufacturing sites in Ireland to boost production of its hugely popular obesity drug and a newly approved treatment for Alzheimer's, the drugmaker said ...

Tempus AI stock reached an important technical milestone, seeing its Relative Strength (RS) Rating jump into the 80-plus ...